Afamelanotide (Scenesse): what the human research actually shows
The approved, well-studied cousin of the research-chemical melanocortin peptides. This is what an FDA-approved melanocortin product looks like when it goes through Phase 3, and the narrow indication is the whole point.
Why I looked into this
Afamelanotide is the peptide I wanted to write about specifically because it is the approved version of a molecule class most readers only meet through the research-chemical internet. Melanotan II, its close cousin, is everywhere online as a tanning peptide. Afamelanotide is in a clinic, in an FDA label, and in a Phase 3 paper in the New England Journal of Medicine.
The contrast is the lesson. Same receptor family, same general mechanism, wildly different evidence base and regulatory standing. I wanted to walk through what Scenesse actually does, who it is for, and what the gap between it and its gray-market relatives actually looks like.
What Afamelanotide actually is
Afamelanotide is a synthetic linear 13-amino-acid peptide analog of alpha-MSH, the endogenous hormone that drives eumelanin production in the skin. It is a potent, long-acting agonist at the melanocortin-1 receptor (MC1R), with additional activity at other melanocortin receptors. Binding MC1R in dermal melanocytes increases eumelanin synthesis, which provides photoprotection against visible and ultraviolet light.
Developed by Clinuvel Pharmaceuticals (originally EpiTan), afamelanotide is delivered as a controlled-release subcutaneous implant under the brand name Scenesse. The implant releases the peptide over a period of months. It is the first and so far only systemic photoprotective therapy approved for erythropoietic protoporphyria.
What the human research shows
Do published human trials exist?
Yes. The approval is anchored to a clean Phase 3 dataset.
The pivotal trial was Langendonk et al., published in the New England Journal of Medicine in 2015. It was a randomized, placebo-controlled, double-blind Phase 3 study in adults with biochemically confirmed erythropoietic protoporphyria. The primary endpoint was pain-free time in direct sunlight over the study period. A separate multi-center open-label program (Biolcati 2015) added real-world observational data across European treatment centers. Both programs were industry funded by Clinuvel.
What evidence actually exists?
The most important trials to know:
- Langendonk JG, Balwani M, Anderson KE, et al. “Afamelanotide for Erythropoietic Protoporphyria.” New England Journal of Medicine. 2015;373(1):48-59. Phase 3 RCT in adults with EPP, total n=74 (US cohort) and n=94 (EU cohort), placebo-controlled. Afamelanotide arm reported significantly more pain-free hours in direct sunlight versus placebo. Industry funded (Clinuvel). PMID 26132944.
- Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. “Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.” British Journal of Dermatology. 2015;172(6):1601-1612. Multi-center open-label data from European expanded-access centers, confirming the EPP benefit over repeated treatment cycles. Industry funded. PMID 25494545.
- More recent smaller trials have explored afamelanotide in vitiligo, solar urticaria, and Hailey-Hailey disease. These are early-stage and do not yet support indications beyond EPP.
What the research does not show
The research does NOT show:
- That afamelanotide is a general-purpose tanning or cosmetic skin-darkening product. The Phase 3 record was run in a rare photosensitivity population, not in healthy adults seeking pigmentation changes.
- Established efficacy in vitiligo, solar urticaria, or other photosensitivity disorders. Early trials exist but are small and not a basis for off-label use outside research settings.
- Long-term (10+ year) data on melanoma risk with repeated use, though post-marketing monitoring is a condition of approval.
- Interchangeability with Melanotan II or research-use-only melanocortin peptides sold online. Afamelanotide is a different molecule with different receptor-selectivity behavior, and the Phase 3 evidence does not transfer.
- Any benefit in people without a diagnosed photosensitivity condition that responds to increased eumelanin.
Known safety signals in humans
The most common adverse events reported in the Phase 3 and long-term observational data were nausea, headache, fatigue, flushing, and skin hyperpigmentation (which is also the mechanism of benefit). Darkening of existing moles and new pigmented lesions have been documented, which is why full-body skin examination before starting and at regular intervals during treatment is built into the approved use pathway.
Because melanocortin-1 receptor activity drives pigmentation, the FDA label requires periodic full-body skin exams by a qualified clinician to monitor for changes in nevi and for any signs of skin cancer. Scenesse is contraindicated in patients with hepatic impairment or a history of melanoma, and caution is advised in patients with other risk factors for skin cancer.
FDA and legal status in the US
Scenesse is the only FDA-approved form of afamelanotide. It is a controlled-release subcutaneous implant placed in-office by a healthcare professional who has completed the manufacturer’s training program. The approval is tightly scoped to adults with a confirmed diagnosis of erythropoietic protoporphyria and a history of phototoxic reactions. Every other use is off-label, and most off-label conditions currently lack a Phase 3 record.
The product class sold online as “Melanotan I” in research-use-only vials is worth naming separately. That material is not the Scenesse implant. It is an unregulated liquid or lyophilized powder with no identity testing, no sterility assurance, no manufacturer accountability, and no connection to the Phase 3 evidence that justifies Scenesse. The FDA has repeatedly warned consumers against injectable melanotan products sold outside approved pathways.
How to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name vendors. I do not link to sellers. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
- Licensed 503A compounding pharmacy
- Third-party certificate of analysis
- Requires a valid prescription
- US-based with verifiable physical address
- Transparent about what they compound and what they do not
- Anonymous crypto-only payment
- “Research use only” labeling loophole
- No COA or in-house testing only
- No physical address or phone contact
- Willingness to sell Category 2 substances for human use
The wrinkle for Afamelanotide specifically
Afamelanotide has a specific identity problem in the gray market. Products sold online as “Melanotan I” are usually marketed as a tanning peptide, not as treatment for a rare photosensitivity disorder, and the material is almost never the controlled-release implant formulation that Scenesse actually is. Analytical surveys of online melanotan products have documented mislabeling and purity variation.
The other wrinkle is that the approved product is an implant placed by a trained clinician who also does the required skin surveillance. A self-administered research-use-only vial removes both the delivery-system difference and the clinical surveillance that the FDA built into the approval. For a melanocortin peptide with an on-label warning about new and evolving pigmented lesions, that surveillance is not a paperwork detail.
Cost reality
Scenesse is one of the most expensive peptides on this site by a wide margin. The list price per implant in the US runs into the tens of thousands of dollars, and patients typically receive multiple implants per year depending on sun-exposure needs. Insurance coverage for EPP is the normal pathway, and out-of-pocket cost outside that pathway is a meaningful barrier even for patients with the approved indication.
Research-use-only melanotan products sell online for a tiny fraction of that. The economic gradient is dramatic, and it is the single biggest reason people end up with a vial of something that is not what the label claims.
Questions worth asking any source
- Is this a Scenesse implant placed by a healthcare professional certified under the manufacturer’s Restricted Distribution Program, or is it something else?
- If the product is not a certified Scenesse implant, what is it, who made it, and is there a certificate of analysis from an independent third-party laboratory confirming identity as afamelanotide?
- Does the product come with the full FDA-approved prescribing information, including the skin-surveillance requirement and the hepatic contraindication?
- Is the clinician placing the implant performing the full-body skin examination at the intervals the label requires, and are they trained to monitor for nevus changes in a patient on a melanocortin agonist?
- Is the seller willing to ship without a prescription and without a certified clinician in the loop? If yes, that answer alone tells you what kind of operation you are dealing with.
My honest take
Opinion, not evidence
This section is opinion. I am not endorsing use of this peptide. Everything above this line is sourced from the published record. Everything below is my personal perspective as one pseudonymous reader and one person who has used this peptide. Your situation is not my situation. Do not treat this as a recommendation.
I have not used Afamelanotide. I do not have EPP, and there is no credible off-label case for a melanocortin agonist in a person who does not have a diagnosed photosensitivity condition. The Phase 3 evidence base is the whole story, and it is tightly scoped to a population I am not in.
What I do take seriously is what this monograph is actually for, which is contrast. Afamelanotide and Melanotan II are close chemical cousins. One has a Phase 3 paper in NEJM, an FDA label, a Restricted Distribution Program, and a skin-surveillance requirement. The other has case reports of hospitalization and no approval anywhere. That asymmetry is not a marketing gap. It is what the regulatory system is for.
The cost story is real. Scenesse is expensive enough that even patients with the approved indication sometimes cannot access it without insurance help, and that price tag is what drives the gray market for cheaper melanotan products sold as tanning peptides. The cheaper product is not the same molecule as the approved one, and the skin-surveillance piece that makes melanocortin use safer is absent by definition when a clinician is not in the loop.
For a curious reader, Langendonk 2015 in NEJM is the single most useful paper to read for this peptide. For someone with EPP, the pharmacy and Restricted Distribution Program pathway is the only pathway the evidence base applies to. For someone considering research-use-only melanotan for cosmetic tanning, the Melanotan II monograph on this site has the safety case reports worth reading before anything else.
Questions to ask your doctor
If you are considering Afamelanotide, or if you are already using it and want to have an honest conversation with a clinician, these are the questions I would bring in with me.
- Do I actually meet the diagnostic criteria for erythropoietic protoporphyria that the Scenesse label requires, and has the biochemical confirmation been done?
- Are you certified under the Scenesse Restricted Distribution Program, and if not, where is the nearest certified center?
- What is your plan for the full-body skin examination the label requires before I start, and at what intervals after that?
- Given the hepatic contraindication and skin-cancer precautions on the label, are there any aspects of my medical history you want to review before I am a candidate?
- If I notice a new or changing pigmented lesion while on treatment, what is the exact protocol for contacting you, and at what threshold should I stop and be seen?
- If cost or insurance coverage is the issue, what patient-support programs exist for Scenesse, and what is your view on any gray-market melanotan alternatives patients sometimes ask about?
What to do next
Read Langendonk 2015
The NEJM Phase 3 paper on afamelanotide for EPP is free to read in abstract form on PubMed and is the cleanest single-document view of what the approval is built on.
Open the primer →Go to a certified clinician
Scenesse is placed under a Restricted Distribution Program by a trained healthcare professional. Bring the visit-prep packet and ask about EPP diagnosis, skin surveillance, and insurance coverage out loud.
Get the packet →Scenesse, not research chemical
The Phase 3 evidence applies to the Scenesse implant placed in a certified clinic with the required skin monitoring. It does not apply to research-use-only melanotan vials sold online as tanning peptides.
Open the checklist →Sources
- Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FP, Sijbrands EJ, de Rooij FW, Naik H, Levy C, Minder E. “Afamelanotide for Erythropoietic Protoporphyria.” New England Journal of Medicine. 2015;373(1):48-59. Industry funded (Clinuvel). PMID 26132944.
- Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. “Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.” British Journal of Dermatology. 2015;172(6):1601-1612. Industry funded. PMID 25494545.
- FDA Prescribing Information, Scenesse (afamelanotide implant). Scenesse label (2019).
- FDA Press Announcement. “FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder.” October 8, 2019.
- European Medicines Agency. Scenesse (afamelanotide) EPAR, initial authorization 2014, subsequent updates.
- Minder EI, Barman-Aksozen J. “Iron and erythropoietic porphyrias.” Haematologica. 2015;100(10):1213-1214. Background review on EPP disease mechanism.
I cite sources above to show the reader what is available to read. Inclusion does not imply endorsement of any claim. Every preclinical reference is flagged as animal or in-vitro only.
Related monographs
Melanotan II
The unapproved cousin. Same receptor family, zero FDA record, documented case reports of serious adverse events. Read alongside Afamelanotide for the full melanocortin contrast.
PT-141 (Bremelanotide)
The other FDA-approved melanocortin peptide, for hypoactive sexual desire disorder. Same receptor family, different indication, useful reference for what Phase 3 melanocortin data looks like.
Oxytocin
A separate neuropeptide with its own approved and off-label use patterns. A useful comparison for how an approved peptide gets misread in the online conversation.